NeOnc Technologies Holdings is trading at $4.00 (8.8% up) today following positive regulatory news. The company announced receipt of written feedback from the U.S. Food and Drug Administration (FDA) regarding the chemistry, manufacturing, and controls (CMC) development program for its drug candidate NEO212. The FDA indicated that NeOnc's proposed approach to CMC development appears reasonable.